Thursday, 5 November 2026European Markets

SPAREBANKEN ØST And BANK OF IRELAND GP Have A High Dividend Yield And Return On Equity In The Banks - Regional Industry.

Loading stream...

(VIANEWS) - SPAREBANKEN ØST (SPOG.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Banks - Regional industry.

Financial Asset Price Forward Dividend Yield Return on Equity
SPAREBANKEN ØST (SPOG.OL) kr54.64 9.79% 10.59%
BANK OF IRELAND GP (BIRG.IR) €9.98 6.14% 13.3%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. SPAREBANKEN ØST (SPOG.OL)

9.79% Forward Dividend Yield and 10.59% Return On Equity

Sparebanken Øst operates as a savings bank in Eastern Norway. The company offers financial products, such as savings, credit, and payment products; current accounts; home mortgage loans; and mortgage loans for new and used cars. It also provides vehicles, houses and contents, boats, and leisure insurance products, as well as life and health insurance products; and shares and funds trading services. In addition, the company buys, sells, and stores cryptocurrencies, as well as operates, manages, leases, and sells real estate properties. The company was founded in 1843 and is headquartered in Drammen, Norway.

Earnings Per Share

As for profitability, SPAREBANKEN ØST has a trailing twelve months EPS of kr7.75.

PE Ratio

SPAREBANKEN ØST has a trailing twelve months price to earnings ratio of 7.05. Meaning, the purchaser of the share is investing kr7.05 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.59%.

More news about SPAREBANKEN ØST.

2. BANK OF IRELAND GP (BIRG.IR)

6.14% Forward Dividend Yield and 13.3% Return On Equity

Bank of Ireland Group plc provides various banking and financial products and services. It provides current and savings accounts, and business deposits and accounts; personal, car, home improvement, graduate, motor finance, and student loans, as well as overdrafts; and business and farming loans, green business, insurance premium finance, invoice finance, hire purchase, and leasing services. The company also offers international payments and credit cards; protection overview, mortgage protection, life cover, specified illness cover, income protection, protection for individuals, and protection for families; pensions; investments; foreign exchange, treasury services, leveraged acquisition and property finance services; personal products; and premier and private banking services. In addition, it provides home, car, travel, and life insurance products. The company was founded in 1783 and is headquartered in Dublin, Ireland.

Earnings Per Share

As for profitability, BANK OF IRELAND GP has a trailing twelve months EPS of €1.4.

PE Ratio

BANK OF IRELAND GP has a trailing twelve months price to earnings ratio of 7.13. Meaning, the purchaser of the share is investing €7.13 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.3%.

Moving Average

BANK OF IRELAND GP's value is below its 50-day moving average of €10.15 and above its 200-day moving average of €9.08.

More news about BANK OF IRELAND GP.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com